Laverock Therapeutics has announces its in vivo programmes spanning CAR-T and genetic medicine. Building on the company’s progress in ex vivo cell therapies, the addition of in vivo programmes to its therapeutic pipeline expands Laverock’s ability to address some of the most significant challenges in oncology and genetic medicine. Laverock’s platform technology enables programmable, tunable and multiplex gene control for both endogenous targets and for transgenically expressed payloads. The platform has been validated across multiple cell therapy applications, including armoured autologous T cells and iPSC-derived macrophages targeting solid tumours. Laverock’s in vivo programmes will provide enhanced efficacy, safety, accessibility, and scalability for CAR-T, and allow the company to address indications with high unmet need in genetic medicine.